No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Ascendis Pharma (ASND) and BioNTech SE (BNTX)
JMP Securities Maintains Pharvaris(PHVS.US) With Buy Rating, Cuts Target Price to $46
We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Pharvaris's Strategic Progress in HAE Pipeline Drives Buy Rating and $30 Price Target
Oppenheimer Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $42
Oppenheimer Remains a Buy on Pharvaris (PHVS)